Market: NASD |
Currency: USD
Address: Toowong Tower
Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. was incorporated in 1999 and is based in Toowong, Australia.
Show more
📈 Anteris Technologies Global Corp. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$13.84
-
Upside/Downside from Analyst Target:
244.25%
-
Broker Call:
6
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
<0%
-
Upcoming Earnings Date:
2025-11-07
-
EPS Estimate:
-0.57
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Anteris Technologies Global Corp.
Date | Reported EPS |
---|
2025-11-06 (estimated upcoming) | - |
2025-08-11 | -0.58 |
2025-05-13 | -0.61 |
📰 Related News & Research
🔍 View more Reports